GO
Loading...

Amgen Inc

More

  • Midday Glance: Biotechnology companies Friday, 26 Dec 2014 | 1:20 PM ET

    Amgen Inc. rose $2.54 or 1.6 percent, to $163.21. Biogen Idec rose$. 53 or. 2 percent, to $341.41. Celgene Corp. rose $3.29 or 3.0 percent, to $112.89.

  • Early Glance: Biotechnology companies Friday, 26 Dec 2014 | 10:23 AM ET

    Amgen Inc. rose $2.52 or 1.6 percent, to $163.19. Biogen Idec rose $1.65 or. 5 percent, to $342.54. Celgene Corp. rose $3.15 or 2.9 percent, to $112.75.

  • Early Glance: Biotechnology companies Wednesday, 24 Dec 2014 | 10:23 AM ET

    Amgen Inc. rose $4.40 or 2.8 percent, to $161.92. Biogen Idec rose $4.11 or 1.2 percent, to $339.87. Celgene Corp. rose $3.71 or 3.5 percent, to $109.83.

  • Final Glance: Biotechnology companies Tuesday, 23 Dec 2014 | 6:06 PM ET

    Amgen Inc. fell $7.01 or 4.3 percent, to $157.52. Biogen Idec fell $16.53 or 4.7 percent, to $335.76. Celgene Corp. fell $7.38 or 6.5 percent, to $106.12.

  • Midday Glance: Biotechnology companies Tuesday, 23 Dec 2014 | 1:22 PM ET

    Amgen Inc. fell $9.68 or 5.9 percent, to $154.85. Biogen Idec fell $23.27 or 6.6 percent, to $329.02. Celgene Corp. fell $9.05 or 8.0 percent, to $104.46.

  • LOS ANGELES, Dec 23- Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly...

  • LOS ANGELES, Dec 23- Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly...

  • Final Glance: Biotechnology companies Monday, 22 Dec 2014 | 7:19 PM ET

    Amgen Inc. fell $5.64 or 3.3 percent, to $164.53. Biogen Idec fell $8.38 or 2.3 percent, to $352.29. Celgene Corp. fell $3.68 or 3.1 percent, to $113.50.

  • Dec 22- The largest U.S. pharmacy benefit manager said on Monday it has lined up a cheaper price for AbbVie Inc's newly approved hepatitis C treatment and, in most cases, will no longer cover Gilead Sciences Inc's treatments after trying for nearly a year to win a deeper discount. Express Scripts' move reignited investor concerns that pharmaceutical companies...

  • Midday Glance: Biotechnology companies Monday, 22 Dec 2014 | 1:22 PM ET

    Amgen Inc. fell $3.99 or 2.3 percent, to $166.18. Biogen Idec fell $4.67 or 1.3 percent, to $356.00. Celgene Corp. fell $2.48 or 2.1 percent, to $114.70.

  • Early Glance: Biotechnology companies Monday, 22 Dec 2014 | 10:22 AM ET

    Amgen Inc. fell $3.09 or 1.8 percent, to $167.08. Biogen Idec fell $8.52 or 2.4 percent, to $352.15. Celgene Corp. fell $2.48 or 2.1 percent, to $114.70.

  • Final Glance: Biotechnology companies Friday, 19 Dec 2014 | 6:41 PM ET

    Amgen Inc. rose $1.69 or 1.0 percent, to $170.17. Biogen Idec rose $6.97 or 2.0 percent, to $360.67. Celgene Corp. rose$. 70 or. 6 percent, to $117.18.

  • Dec 19- AstraZeneca Plc's ovarian cancer drug has been granted an accelerated approval by the U.S. health regulator, a day after the treatment was approved by the European Commission. AstraZeneca expects potential sales of around $2 billion a year from the drug. London- based AstraZeneca's U.S.-listed shares were down about 1 percent at $71.41 in afternoon...

  • Midday Glance: Biotechnology companies Friday, 19 Dec 2014 | 1:25 PM ET

    Amgen Inc. rose$. 07 or percent, to $168.55. Biogen Idec rose $4.57 or 1.3 percent, to $358.27. Celgene Corp. rose$. 44 or. 4 percent, to $116.92.

  • Early Glance: Biotechnology companies Friday, 19 Dec 2014 | 10:20 AM ET

    Amgen Inc. fell$. 37 or. 2 percent, to $168.11. Biogen Idec fell $3.70 or 1.0 percent, to $350.00. Celgene Corp. rose$. 12 or. 1 percent, to $116.60.

  • Final Glance: Biotechnology companies Thursday, 18 Dec 2014 | 8:08 PM ET

    Amgen Inc. rose $5.00 or 3.1 percent, to $168.48. Biogen Idec rose $20.81 or 6.3 percent, to $353.70. Celgene Corp. rose $3.66 or 3.2 percent, to $116.48.

  • Midday Glance: Biotechnology companies Thursday, 18 Dec 2014 | 1:48 PM ET

    Amgen Inc. rose $3.32 or 2.0 percent, to $166.80. Biogen Idec rose $15.05 or 4.5 percent, to $347.94. Celgene Corp. rose $2.68 or 2.4 percent, to $115.50.

  • Early Glance: Biotechnology companies Thursday, 18 Dec 2014 | 11:11 AM ET

    Amgen Inc. rose $2.18 or 1.3 percent, to $165.66. Biogen Idec rose $12.84 or 3.9 percent, to $345.73. Celgene Corp. rose $2.63 or 2.3 percent, to $115.45.

  • Final Glance: Biotechnology companies Wednesday, 17 Dec 2014 | 7:08 PM ET

    Amgen Inc. rose $4.04 or 2.5 percent, to $163.48. Biogen Idec rose $7.76 or 2.4 percent, to $332.89. Celgene Corp. rose $2.73 or 2.5 percent, to $112.82.

  • Leaked Sony emails show Loeb influence on studio execs Wednesday, 17 Dec 2014 | 3:11 PM ET

    TOKYO/ BOSTON, Dec 17- Sony Corp movie executives kept up a dialogue with hedge fund titan Daniel Loeb, even after rebuffing the billionaire investor's proposal to sell up to one-fifth of the studio's entertainment business, leaked emails show. Loeb's New York- based Third Point took a 7 percent stake in the company in May 2013 and suggested that proceeds from a...